Advertisement

Promethazine Injection

[01 December 2014]

Products Affected - Description

Promethazine injection, Hospira
25 mg/mL 1 mL Carpuject syringe (NDC 00409-2312-31)
 
Promethazine injection, Teva
25 mg/mL 1 mL vial (NDC 00703-2191-04)
50 mg/mL 1 mL vial (NDC 00703-2201-04)
 
Promethazine injection, West-Ward
25 mg/mL 1 mL ampule (NDC 00641-1495-35)
50 mg/mL 1 mL ampule (NDC 00641-1496-35)
 
Phenergan injection, West-Ward
25 mg/mL 1 mL ampule (NDC 00641-6082-25)
50 mg/mL 1 mL ampule (NDC 00641-6083-25)

Reason for the Shortage

  • Teva states the shortage is due to manufacturing delays.
  • West-Ward states the shortage was due to manufacturing delays. The company has also changed the NDC numbers for products that were formerly Baxter products.
  • Hospira states the shortage is due to manufacturing delays.

Available Products

Promethazine injection, West-Ward
25 mg/mL 1 mL vial (NDC 00641-0928-25)
50 mg/mL 1 mL vial (NDC 00641-0929-25)
Phenergan injection, West-Ward
25 mg/mL 1 mL vial (NDC 00641-6084-25)
50 mg/mL 1 mL vial (NDC 00641-6085-25)
Promethazine injection, X-Gen
25 mg/mL 1 mL ampule (NDC 39822-5500-03)
50 mg/mL 1 mL ampule (NDC 39822-5500-06)

Estimated Resupply Dates

  • Hospira has promethazine 25 mg/mL 1 mL Carpuject syringes on back order and the company cannot estimate a release date.
  • Teva has all promethazine injection presentations on back order and the company estimates a release date of 3rd quarter 2015.
  • West-Ward has promethazine 25 mg/mL and 50 mg/mL 1 mL ampules on back order and the company estimates a release date in mid- to late-December 2014. West-Ward has Phenergan 50 mg/mL 1 mL ampules available but have short expiration dating (June or October 2015). Phenergan 25 mg/mL 1 mL ampules in 25 count are on back order and the company cannot estimate a release date. West-Ward has several products available with good dating and with short expiration dating: promethazine 25 mg/mL 1 mL vials (February or March 2015), promethazine 50 mg/mL 1 mL vials (May 2015), Phenergan 25 mg/mL 1 mL vials (August 2015), and Phenergan 50 mg/mL 1 mL vials (May 2015).

Related Shortages

Updated

December 1, 2014; November 19, 2014; November 10, 2014; October 1, 2014; August 28, 2014; July 31, 2014; July 10, 2014; May 6, 2014; April 23, 2014; March 27, 2014; January 24, 2014; November 11, 2013; September 18, 2013; August 15, 2013; July 3, 2013; June 11, 2013; April 30, 2013; March 26, 2013; February 20, 2013; February 13, 2013; January 30, 2013; January 18, 2013; November 9, 2012; September 7, 2012; August 13, 2012; July 20, 2012; June 21, 2012; May 7, 2012; March 9, 2012; February 10, 2012; January 24, 2012; December 9, 2011; November 30, 2011; September 6, 2011; July 15, 2011; May 24, 2011; April 6, 2011; March 18, 2011; February 9, 2011; January 27, 2011; December 15, 2010; November 4, 2010; October 14, 2010; October 1, 2010; September 9, 2010; August 31, 2010; August 18, 2010; July 30, 2010; June 22, 2010, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement